NASDAQ:PCRX - Pacira Pharmaceuticals Stock Price, Price Target & More

$34.50 -0.80 (-2.27 %)
(As of 04/26/2018 09:36 AM ET)
Previous Close$35.30
Today's Range$32.56 - $36.35
52-Week Range$26.95 - $52.47
Volume1.27 million shs
Average Volume1.16 million shs
Market Capitalization$1.44 billion
P/E Ratio-59.48
Dividend YieldN/A
Beta1.77

About Pacira Pharmaceuticals (NASDAQ:PCRX)

Pacira Pharmaceuticals logoPacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company's lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.

Receive PCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:PCRX
CUSIP69512710
Phone973-254-3560

Debt

Debt-to-Equity Ratio0.99%
Current Ratio6.96%
Quick Ratio6.22%

Price-To-Earnings

Trailing P/E Ratio-59.48
Forward P/E Ratio-67.65
P/E GrowthN/A

Sales & Book Value

Annual Sales$286.63 million
Price / Sales4.90
Cash Flow$0.06 per share
Price / Cash574.69
Book Value$6.89 per share
Price / Book5.01

Profitability

EPS (Most Recent Fiscal Year)($0.58)
Net Income$-42,610,000.00
Net Margins-14.87%
Return on Equity-8.55%
Return on Assets-3.77%

Miscellaneous

Employees489
Outstanding Shares40,710,000

How to Become a New Pot Stock Millionaire

Pacira Pharmaceuticals (NASDAQ:PCRX) Frequently Asked Questions

What is Pacira Pharmaceuticals' stock symbol?

Pacira Pharmaceuticals trades on the NASDAQ under the ticker symbol "PCRX."

How were Pacira Pharmaceuticals' earnings last quarter?

Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) announced its quarterly earnings results on Wednesday, February, 28th. The company reported $0.38 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.46. The company had revenue of $79.08 million for the quarter, compared to the consensus estimate of $79.06 million. Pacira Pharmaceuticals had a negative return on equity of 8.55% and a negative net margin of 14.87%. The firm's revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period last year, the firm earned $0.09 EPS. View Pacira Pharmaceuticals' Earnings History.

When is Pacira Pharmaceuticals' next earnings date?

Pacira Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Pacira Pharmaceuticals.

What price target have analysts set for PCRX?

20 equities research analysts have issued 12-month target prices for Pacira Pharmaceuticals' shares. Their forecasts range from $27.00 to $80.00. On average, they expect Pacira Pharmaceuticals' stock price to reach $44.50 in the next twelve months. View Analyst Ratings for Pacira Pharmaceuticals.

What are Wall Street analysts saying about Pacira Pharmaceuticals stock?

Here are some recent quotes from research analysts about Pacira Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Pacira fourth-quarter 2017 earnings surpassed estimates while revenues were at par with them. Pacira’s top line mainly comprises contribution from its marketed product Exparel which generated sales of $282.9 million in 2017, up 6.4%. The company’s efforts to expand Exparel's label are encouraging. Pacira remains optimistic of its partnership with J&J to market and promote the use of Exparel, with their sales and medical education teams. However, the company is heavily dependent on Exparel for growth. In February 2018, the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee reviewed the company’s sNDA, and voted six to four against approval of the expanded indication. We believe that this is a concern for the company. However, the company however remains confident and will keep an open dialogue with the FDA to define the best next steps for expanding the Exparel indication." (3/6/2018)
  • 2. Canaccord Genuity analysts commented, "We’re looking for more than two months of data showing solid growth before we become positive on the potential for a meaningful inflection in Exparel use trends, especially with a noisy October that may have benefited from hurricane-related deferred procedures that negatively impacted September volumes. We remain HOLD rated on PCRX shares." (12/29/2017)
  • 3. Cowen Inc analysts commented, "Nerve block data for Exparel is anticipated within the next month, and our consultants." (7/14/2017)

Who are some of Pacira Pharmaceuticals' key competitors?

Who are Pacira Pharmaceuticals' key executives?

Pacira Pharmaceuticals' management team includes the folowing people:
  • Mr. David M. Stack, Chairman and Chief Exec. Officer (Age 68)
  • Mr. Charles A. Reinhart III, Chief Financial Officer (Age 57)
  • Dr. Scott Braunstein, Chief Operating Officer (Age 55)
  • Ms. Kristen Williams J.D., Chief Admin. Officer, Gen. Counsel and Sec. (Age 44)
  • Ms. Lauren Bullaro Riker, Principal Accounting Officer & VP of Fin. (Age 39)

Has Pacira Pharmaceuticals been receiving favorable news coverage?

News stories about PCRX stock have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pacira Pharmaceuticals earned a media sentiment score of 0.15 on Accern's scale. They also assigned media headlines about the company an impact score of 45.34 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Pacira Pharmaceuticals' major shareholders?

Pacira Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include PARTNER FUND MANAGEMENT, L.P. (6.00%). Company insiders that own Pacira Pharmaceuticals stock include David M Stack, James B Jones, James S Scibetta, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Paul J Hastings and Scott Braunstein. View Institutional Ownership Trends for Pacira Pharmaceuticals.

How do I buy shares of Pacira Pharmaceuticals?

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pacira Pharmaceuticals' stock price today?

One share of PCRX stock can currently be purchased for approximately $34.50.

How big of a company is Pacira Pharmaceuticals?

Pacira Pharmaceuticals has a market capitalization of $1.44 billion and generates $286.63 million in revenue each year. The company earns $-42,610,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Pacira Pharmaceuticals employs 489 workers across the globe.

How can I contact Pacira Pharmaceuticals?

Pacira Pharmaceuticals' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]


MarketBeat Community Rating for Pacira Pharmaceuticals (PCRX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  566 (Vote Outperform)
Underperform Votes:  332 (Vote Underperform)
Total Votes:  898
MarketBeat's community ratings are surveys of what our community members think about Pacira Pharmaceuticals and other stocks. Vote "Outperform" if you believe PCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PCRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pacira Pharmaceuticals (NASDAQ:PCRX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
20 Wall Street analysts have issued ratings and price targets for Pacira Pharmaceuticals in the last 12 months. Their average twelve-month price target is $44.50, suggesting that the stock has a possible upside of 28.99%. The high price target for PCRX is $80.00 and the low price target for PCRX is $27.00. There are currently 1 sell rating, 11 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.352.352.452.50
Ratings Breakdown: 1 Sell Rating(s)
11 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
11 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $44.50$44.1875$49.50$51.9231
Price Target Upside: 28.99% upside47.39% upside26.60% upside59.52% upside

Pacira Pharmaceuticals (NASDAQ:PCRX) Consensus Price Target History

Price Target History for Pacira Pharmaceuticals (NASDAQ:PCRX)

Pacira Pharmaceuticals (NASDAQ:PCRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/10/2018JPMorgan ChaseBoost Price TargetNeutral -> Neutral$40.00 -> $43.00LowView Rating Details
4/9/2018WedbushLower Price TargetOutperform$72.00 -> $80.00HighView Rating Details
4/9/2018BMO Capital MarketsBoost Price TargetMarket Perform -> Market Perform$31.00 -> $34.00LowView Rating Details
4/9/2018HC WainwrightReiterated RatingBuy -> Buy$45.00 -> $48.00MediumView Rating Details
4/9/2018Piper JaffraySet Price TargetBuy$44.00MediumView Rating Details
4/9/2018Canaccord GenuityBoost Price TargetHold -> Hold$32.00 -> $34.00MediumView Rating Details
4/8/2018Seaport Global SecuritiesSet Price TargetBuy$48.00MediumView Rating Details
3/21/2018MizuhoLower Price TargetNeutral -> Neutral$44.00 -> $31.00HighView Rating Details
3/1/2018Royal Bank of CanadaSet Price TargetBuy$44.00HighView Rating Details
3/1/2018OppenheimerReiterated RatingHoldHighView Rating Details
2/16/2018Needham & Company LLCDowngradeBuy -> Hold$55.00HighView Rating Details
2/16/2018BarclaysReiterated RatingBuy$40.00HighView Rating Details
1/2/2018Leerink SwannInitiated CoverageMkt Perform -> Market Perform$46.00LowView Rating Details
11/16/2017Janney Montgomery ScottSet Price TargetSell$27.00N/AView Rating Details
11/9/2017Jefferies GroupLower Price TargetBuy$52.00N/AView Rating Details
10/4/2017Bank of AmericaLower Price TargetBuy$46.00 -> $45.00LowView Rating Details
9/28/2017Goldman SachsInitiated CoverageNeutral -> Neutral$41.00MediumView Rating Details
9/7/2017CIBCInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
9/6/2017UBSInitiated CoverageMarket PerformMediumView Rating Details
8/2/2017CowenReiterated RatingHoldMediumView Rating Details
10/7/2016Brean CapitalInitiated CoverageHoldN/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Pacira Pharmaceuticals (NASDAQ:PCRX) Earnings History and Estimates Chart

Earnings by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Pacira Pharmaceuticals (NASDAQ:PCRX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.54)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.15)($0.14)($0.15)
Q2 20182($0.13)($0.12)($0.13)
Q3 20182($0.22)($0.17)($0.20)
Q4 20183($0.13)$0.00($0.07)

Pacira Pharmaceuticals (NASDAQ PCRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018$0.02N/AView Earnings Details
2/28/2018Q4 2017($0.08)$0.38$79.06 million$79.08 millionViewN/AView Earnings Details
11/8/2017Q3 2017($0.04)$0.11$68.99 million$67.30 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.05)($0.11)$73.37 million$70.90 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.23)($0.19)$70.30 million$69.30 millionViewListenView Earnings Details
3/1/2017Q416$0.01$0.09$73.08 million$72.90 millionViewListenView Earnings Details
11/2/2016Q316($0.02)$0.20$67.16 million$68.40 millionViewListenView Earnings Details
8/4/2016Q216$0.03$0.19$67.80 million$69.60 millionViewListenView Earnings Details
5/2/2016Q116$0.07$0.15$67.11 million$65.50 millionViewListenView Earnings Details
2/25/2016Q415$0.27$0.20$68.40 million$69.30 millionViewListenView Earnings Details
10/27/2015Q315$0.15$0.10$60.44 million$62.20 millionViewListenView Earnings Details
7/30/2015Q215$0.04$0.20$62.97 million$59.10 millionViewListenView Earnings Details
4/30/2015Q115$0.02$0.05$61.11 million$58.30 millionViewListenView Earnings Details
2/24/2015Q4$0.27$0.35$61.62 million$61.80 millionViewListenView Earnings Details
10/30/2014Q314$0.10$0.14$52.20 million$52.00 millionViewListenView Earnings Details
7/31/2014Q214($0.21)$0.04$42.20 million$47.20 millionViewListenView Earnings Details
5/1/2014Q1($0.32)($0.19)$35.40 million$36.70 millionViewListenView Earnings Details
2/25/2014Q4($0.31)($0.33)$30.72 million$33.56 millionViewListenView Earnings Details
10/31/2013Q313($0.35)($0.30)$22.10 million$23.30 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.43)($0.42)$16.45 million$17.14 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.49)($0.61)$12.60 million$11.59 millionViewN/AView Earnings Details
3/7/2013Q4 2012($0.41)($0.50)ViewN/AView Earnings Details
11/1/2012Q312($0.44)($0.49)$7.85 million$8.50 millionViewN/AView Earnings Details
8/9/2012Q2 2012($0.43)($0.27)ViewN/AView Earnings Details
5/9/2012Q1 2012($0.39)($0.47)ViewN/AView Earnings Details
3/27/2012Q4 2011($0.54)($0.58)ViewN/AView Earnings Details
10/31/2011Q3 2011($0.59)($0.55)ViewN/AView Earnings Details
8/11/2011Q2 2011($0.58)($0.51)ViewN/AView Earnings Details
5/11/2011Q1 2011($0.53)($0.98)ViewN/AView Earnings Details
3/31/2011Q4 2010($11.95)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Pacira Pharmaceuticals (NASDAQ:PCRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Pacira Pharmaceuticals (NASDAQ PCRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.60%
Insider Trading History for Pacira Pharmaceuticals (NASDAQ:PCRX)
Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Pacira Pharmaceuticals (NASDAQ PCRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/10/2018David M. StackCEOSell28,885$40.19$1,160,888.15View SEC Filing  
12/15/2017Lauren Bullaro RikerVPSell340$43.70$14,858.00View SEC Filing  
11/20/2017James B. JonesSVPSell850$41.11$34,943.50View SEC Filing  
11/17/2017Kristen Marie WilliamsCAOSell10,000$40.00$400,000.0023,455View SEC Filing  
11/15/2017David M StackCEOSell58,885$38.34$2,257,650.90159,164View SEC Filing  
11/10/2017Mark A KronenfeldDirectorBuy1,000$41.60$41,600.006,795View SEC Filing  
8/22/2017Paul J HastingsDirectorSell1,044$36.15$37,740.603,518View SEC Filing  
8/15/2017David M StackCEOSell28,885$36.37$1,050,547.45159,164View SEC Filing  
8/15/2017Kristen Marie WilliamsCAOSell3,461$36.75$127,191.7521,312View SEC Filing  
8/8/2017Mark FroimsonDirectorBuy100$37.13$3,713.00100View SEC Filing  
6/5/2017David M StackCEOSell4,311$43.32$186,752.5259,559View SEC Filing  
6/5/2017James S ScibettaPresidentSell1,966$43.32$85,167.1225,118View SEC Filing  
6/5/2017Kristen Marie WilliamsCAOSell1,877$43.32$81,311.6413,773View SEC Filing  
6/5/2017Lauren Bullaro RikerVPSell601$43.32$26,035.32View SEC Filing  
6/5/2017Scott BraunsteinSVPSell768$43.32$33,269.769,982View SEC Filing  
5/15/2017James S ScibettaPresidentSell20,000$51.20$1,024,000.0047,084View SEC Filing  
5/15/2017Kristen Marie WilliamsCAOSell21,041$50.86$1,070,145.2618,775View SEC Filing  
1/17/2017David M. StackCEOSell15,000$38.41$576,150.00View SEC Filing  
1/17/2017James S ScibettaPresidentSell20,000$38.53$770,600.0029,457View SEC Filing  
8/15/2016David M. StackCEOSell15,000$45.32$679,800.00View SEC Filing  
8/15/2016James S. ScibettaPresidentSell25,000$45.21$1,130,250.00View SEC Filing  
6/7/2016Lauren Bullaro RikerVPSell938$47.66$44,705.085,945View SEC Filing  
6/6/2016Kristen Marie WilliamsCAOSell600$47.20$28,320.006,900View SEC Filing  
6/6/2016Lauren Bullaro RikerVPSell321$47.20$15,151.205,945View SEC Filing  
6/6/2016Mark A KronenfeldDirectorSell900$46.95$42,255.002,950View SEC Filing  
4/15/2016David M StackCEOSell25,000$64.14$1,603,500.0025,285View SEC Filing  
1/29/2016Scott BraunsteinSVPBuy2,000$58.92$117,840.002,000View SEC Filing  
1/27/2016James B JonesSVPBuy500$62.50$31,250.001,500View SEC Filing  
1/15/2016David M. StackCEOSell15,000$63.84$957,600.00285View SEC Filing  
1/12/2016James B JonesSVPBuy1,000$66.00$66,000.001,000View SEC Filing  
1/12/2016John P Phd LongeneckerDirectorBuy300$66.55$19,965.002,300View SEC Filing  
10/15/2015David M. StackCEOSell15,000$37.57$563,550.00176View SEC Filing  
9/11/2015James S ScibettaCFOBuy5,000$61.37$306,850.0010,504View SEC Filing  
8/17/2015Paul J HastingsDirectorSell3,000$60.02$180,060.00View SEC Filing  
7/15/2015David M StackCEOSell15,000$67.78$1,016,700.00View SEC Filing  
4/15/2015David M StackCEOSell25,000$90.50$2,262,500.00View SEC Filing  
4/10/2015Paul J HastingsDirectorSell2,500$88.00$220,000.00View SEC Filing  
3/16/2015Lauren Bullaro RikerDirectorSell5,000$95.34$476,700.00View SEC Filing  
3/13/2015Gary W PaceDirectorBuy1,000$93.83$93,830.00View SEC Filing  
2/6/2015James S ScibettaCFOSell15,000$111.22$1,668,300.00View SEC Filing  
1/15/2015David M StackCEOSell15,000$97.52$1,462,800.00View SEC Filing  
1/12/2015Paul J HastingsDirectorSell2,500$94.06$235,150.00View SEC Filing  
12/29/2014John P Phd LongeneckerDirectorSell1,000$93.32$93,320.00View SEC Filing  
12/5/2014Dennis L WingerDirectorBuy2,645$94.54$250,058.30View SEC Filing  
11/7/2014James S ScibettaCFOSell15,000$87.18$1,307,700.00View SEC Filing  
11/7/2014Taunia MarkvickaSVPBuy230$86.62$19,922.60View SEC Filing  
10/10/2014Paul J HastingsDirectorSell2,500$94.87$237,175.00View SEC Filing  
9/29/2014John P Phd LongeneckerDirectorSell1,000$96.40$96,400.00View SEC Filing  
8/29/2014Andreas WickiDirectorSell21,494$108.11$2,323,716.34View SEC Filing  
8/27/2014Andreas WickiDirectorSell55,813$108.08$6,032,269.04View SEC Filing  
8/26/2014Andreas WickiDirectorSell24,207$108.11$2,617,018.77View SEC Filing  
8/25/2014Andreas WickiDirectorSell30,000$108.07$3,242,100.00View SEC Filing  
8/11/2014Andreas WickiDirectorSell150,000$101.25$15,187,500.00View SEC Filing  
8/8/2014James S ScibettaCFOSell15,000$99.63$1,494,450.00View SEC Filing  
8/7/2014Gary PatouInsiderSell20,000$100.26$2,005,200.00View SEC Filing  
7/15/2014David M StackCEOSell15,000$86.75$1,301,250.00View SEC Filing  
7/14/2014Gary PatouInsiderSell29,700$86.96$2,582,712.00View SEC Filing  
7/10/2014Paul J HastingsDirectorSell2,500$84.41$211,025.00View SEC Filing  
6/6/2014Andreas WickiDirectorSell67,900$82.62$5,609,898.00View SEC Filing  
6/3/2014Andreas WickiDirectorSell68,000$80.69$5,486,920.00View SEC Filing  
5/27/2014Andreas WickiDirectorSell64,400$77.93$5,018,692.00View SEC Filing  
5/21/2014Andreas WickiDirectorSell3,600$77.80$280,080.00View SEC Filing  
5/12/2014Gary PatouInsiderSell30,000$74.39$2,231,700.00View SEC Filing  
5/9/2014David StackCEOSell25,000$73.94$1,848,500.001,208View SEC Filing  
5/9/2014Laura BregeDirectorSell10,000$73.85$738,500.00View SEC Filing  
5/8/2014Andreas WickiDirectorSell23,220$75.76$1,759,147.20View SEC Filing  
5/8/2014James ScibettaCFOSell15,000$75.05$1,125,750.005,000View SEC Filing  
5/7/2014Andreas WickiDirectorSell44,780$75.78$3,393,428.40View SEC Filing  
3/28/2014John Phd LongeneckerDirectorSell1,000$64.63$64,630.00View SEC Filing  
3/6/2014Andreas WickiDirectorSell24,887$80.16$1,994,941.92View SEC Filing  
12/30/2013David StackCEOSell15,000$55.84$837,600.002,987View SEC Filing  
12/30/2013James ScibettaCFOSell10,000$55.55$555,500.005,000View SEC Filing  
12/30/2013John Phd LongeneckerDirectorSell2,500$55.55$138,875.00View SEC Filing  
10/1/2013Gary PatouInsiderSell20,000$48.92$978,400.00View SEC Filing  
9/11/2013Andreas WickiDirectorSell17,783$37.25$662,416.75View SEC Filing  
8/14/2013Taunia MarkvickaVPSell14,700$37.00$543,900.00View SEC Filing  
7/22/2013Andreas WickiDirectorSell75,958$35.06$2,663,087.48View SEC Filing  
7/18/2013Andreas WickiDirectorSell25,560$33.45$854,982.00View SEC Filing  
7/16/2013Andreas WickiDirectorSell48,482$33.28$1,613,480.96View SEC Filing  
7/12/2013Taunia MarkvickaVPSell29,754$32.00$952,128.00View SEC Filing  
7/11/2013Andreas WickiDirectorSell80,000$31.48$2,518,400.00View SEC Filing  
7/5/2013Andreas WickiDirectorSell44,021$30.80$1,355,846.80View SEC Filing  
7/3/2013Andreas WickiDirectorSell114,448$30.21$3,457,474.08View SEC Filing  
7/2/2013Gary PatouInsiderSell40,000$29.44$1,177,600.00View SEC Filing  
6/28/2013David M StackCEOSell15,000$28.73$430,950.00View SEC Filing  
6/28/2013James S ScibettaCFOSell10,000$28.05$280,500.00View SEC Filing  
6/28/2013John P Phd LongeneckerDirectorSell2,000$28.09$56,180.00View SEC Filing  
6/24/2013Fred A MiddletonDirectorSell75,900$29.13$2,210,967.00View SEC Filing  
6/20/2013Fred A MiddletonDirectorSell144,100$29.32$4,225,012.00View SEC Filing  
6/19/2013Andreas WickiDirectorSell35,407$29.90$1,058,669.30View SEC Filing  
6/17/2013Andreas WickiDirectorSell50,145$29.86$1,497,329.70View SEC Filing  
6/13/2013John PrattInsiderSell21,032$30.00$630,960.00View SEC Filing  
6/13/2013Luke EvninDirectorSell22,746$30.07$683,972.22View SEC Filing  
6/12/2013Andreas WickiDirectorSell4,409$30.00$132,270.00View SEC Filing  
6/11/2013Andreas WickiDirectorSell11,500$30.00$345,000.00View SEC Filing  
6/11/2013John PrattInsiderSell18,343$30.00$550,290.00View SEC Filing  
6/5/2013Andreas WickiDirectorSell15,500$30.26$469,030.00View SEC Filing  
6/3/2013Andreas WickiDirectorSell1,900$30.00$57,000.00View SEC Filing  
5/31/2013Luke EvninDirectorSell54,517$30.00$1,635,510.00View SEC Filing  
5/29/2013Luke EvninDirectorSell215,528$30.86$6,651,194.08View SEC Filing  
5/22/2013Andreas WickiDirectorSell18,471$30.00$554,130.00View SEC Filing  
5/20/2013Andreas WickiDirectorSell14,374$30.00$431,220.00View SEC Filing  
3/25/2013Andreas WickiDirectorSell290,900$27.95$8,130,655.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Pacira Pharmaceuticals (NASDAQ PCRX) News Headlines

Source:
DateHeadline
Pacira Pharmaceuticals (PCRX) Set to Announce Earnings on WednesdayPacira Pharmaceuticals (PCRX) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - April 25 at 7:08 AM
 Brokerages Anticipate Pacira Pharmaceuticals Inc. (PCRX) to Post $0.06 Earnings Per Share Brokerages Anticipate Pacira Pharmaceuticals Inc. (PCRX) to Post $0.06 Earnings Per Share
www.americanbankingnews.com - April 25 at 5:20 AM
Noteworthy Friday Option Activity: PCRX, GRA, CNoteworthy Friday Option Activity: PCRX, GRA, C
www.nasdaq.com - April 20 at 4:55 PM
Pacira Pharmaceuticals (PCRX) Given a $58.00 Price Target at Royal Bank of CanadaPacira Pharmaceuticals (PCRX) Given a $58.00 Price Target at Royal Bank of Canada
www.americanbankingnews.com - April 20 at 3:00 PM
Pacira Pharmaceuticals (PCRX) PT Set at $56.00 by Canaccord GenuityPacira Pharmaceuticals (PCRX) PT Set at $56.00 by Canaccord Genuity
www.americanbankingnews.com - April 15 at 8:22 PM
Pacira Pharmaceuticals (PCRX) Lowered to Sell at BidaskClubPacira Pharmaceuticals (PCRX) Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 15 at 12:34 PM
Pacira Pharmaceuticals (PCRX) PT Set at $58.00 by Royal Bank of CanadaPacira Pharmaceuticals (PCRX) PT Set at $58.00 by Royal Bank of Canada
www.americanbankingnews.com - April 15 at 8:37 AM
BidaskClub Downgrades Pacira Pharmaceuticals (PCRX) to Strong SellBidaskClub Downgrades Pacira Pharmaceuticals (PCRX) to Strong Sell
www.americanbankingnews.com - April 14 at 12:17 AM
Pacira Pharmaceuticals (PCRX) PT Lowered to $40.00 at BMO Capital MarketsPacira Pharmaceuticals (PCRX) PT Lowered to $40.00 at BMO Capital Markets
www.americanbankingnews.com - April 13 at 3:16 PM
FY2018 EPS Estimates for Pacira Pharmaceuticals Inc. Increased by Analyst (PCRX)FY2018 EPS Estimates for Pacira Pharmaceuticals Inc. Increased by Analyst (PCRX)
www.americanbankingnews.com - April 12 at 7:37 AM
Pacira Pharmaceuticals Inc. to Post Q1 2018 Earnings of ($0.14) Per Share, Wedbush Forecasts (PCRX)Pacira Pharmaceuticals Inc. to Post Q1 2018 Earnings of ($0.14) Per Share, Wedbush Forecasts (PCRX)
www.americanbankingnews.com - April 12 at 7:09 AM
Pacira Pharmaceuticals Inc. Expected to Earn Q1 2018 Earnings of ($0.15) Per Share (PCRX)Pacira Pharmaceuticals Inc. Expected to Earn Q1 2018 Earnings of ($0.15) Per Share (PCRX)
www.americanbankingnews.com - April 11 at 8:01 AM
Pacira Pharmaceuticals (PCRX) PT Raised to $43.00Pacira Pharmaceuticals (PCRX) PT Raised to $43.00
www.americanbankingnews.com - April 10 at 10:57 AM
FDA Okays Label Expansion of Pacira's Exparel's, Stock UpFDA Okays Label Expansion of Pacira's Exparel's, Stock Up
finance.yahoo.com - April 10 at 9:10 AM
Pacira Pharmaceuticals Sees Unusually Large Options Volume (PCRX)Pacira Pharmaceuticals Sees Unusually Large Options Volume (PCRX)
www.americanbankingnews.com - April 10 at 7:45 AM
$74.39 Million in Sales Expected for Pacira Pharmaceuticals Inc. (PCRX) This Quarter$74.39 Million in Sales Expected for Pacira Pharmaceuticals Inc. (PCRX) This Quarter
www.americanbankingnews.com - April 10 at 4:15 AM
Pacira Pharmaceuticals (PCRX) Lifted to "Hold" at ValuEnginePacira Pharmaceuticals (PCRX) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - April 10 at 12:33 AM
Mizuho Reiterates "Buy" Rating for Pacira Pharmaceuticals (PCRX)Mizuho Reiterates "Buy" Rating for Pacira Pharmaceuticals (PCRX)
www.americanbankingnews.com - April 9 at 10:56 PM
Pacira Pharmaceuticals (PCRX) Given "Outperform" Rating at WedbushPacira Pharmaceuticals (PCRX) Given "Outperform" Rating at Wedbush
www.americanbankingnews.com - April 9 at 5:16 PM
Why Analysts See Pacira Pharma in a Night and Day ContrastWhy Analysts See Pacira Pharma in a Night and Day Contrast
247wallst.com - April 9 at 4:53 PM
FDA Okays Label Expansion of Paciras Exparels, Stock UpFDA Okays Label Expansion of Pacira's Exparel's, Stock Up
www.zacks.com - April 9 at 4:53 PM
Here’s Why The Latest News Is A Big Deal For Pacira PharmaceuticalsHere’s Why The Latest News Is A Big Deal For Pacira Pharmaceuticals
finance.yahoo.com - April 9 at 4:53 PM
Pacira Pharma (PCRX) Reports FDA Approval of Supplemental New Drug Application for EXPARELPacira Pharma (PCRX) Reports FDA Approval of Supplemental New Drug Application for EXPAREL
www.streetinsider.com - April 9 at 9:04 AM
Pacira Pharmaceuticals (PCRX) Soars: Stock Adds 12.9% in SessionPacira Pharmaceuticals (PCRX) Soars: Stock Adds 12.9% in Session
www.zacks.com - April 9 at 9:04 AM
Pacira Pharmaceuticals (PCRX) PT Raised to $34 at BMO CapitalPacira Pharmaceuticals (PCRX) PT Raised to $34 at BMO Capital
www.streetinsider.com - April 9 at 9:04 AM
Pacira Pharmaceuticals (PCRX) Price Target Raised to $34.00Pacira Pharmaceuticals (PCRX) Price Target Raised to $34.00
www.americanbankingnews.com - April 9 at 8:51 AM
Pacira Pharmaceuticals (PCRX) Receives Hold Rating from JPMorgan ChasePacira Pharmaceuticals (PCRX) Receives Hold Rating from JPMorgan Chase
www.americanbankingnews.com - April 9 at 8:25 AM
HC Wainwright Reaffirms "Buy" Rating for Pacira Pharmaceuticals (PCRX)HC Wainwright Reaffirms "Buy" Rating for Pacira Pharmaceuticals (PCRX)
www.americanbankingnews.com - April 9 at 8:13 AM
Pacira Pharmaceuticals (PCRX) Given a $44.00 Price Target at Piper JaffrayPacira Pharmaceuticals (PCRX) Given a $44.00 Price Target at Piper Jaffray
www.americanbankingnews.com - April 9 at 7:54 AM
Pacira Pharmaceuticals (PCRX) Given a $48.00 Price Target at Seaport Global SecuritiesPacira Pharmaceuticals (PCRX) Given a $48.00 Price Target at Seaport Global Securities
www.americanbankingnews.com - April 9 at 7:54 AM
Pacira Pharmaceuticals (PCRX) "Hold" Rating Reaffirmed at Canaccord GenuityPacira Pharmaceuticals' (PCRX) "Hold" Rating Reaffirmed at Canaccord Genuity
www.americanbankingnews.com - April 9 at 6:02 AM
An Ear To The Pharma: 9 Stocks To Watch This Week (SELB, AGLE, BPMC, MNOV.)An Ear To The Pharma: 9 Stocks To Watch This Week (SELB, AGLE, BPMC, MNOV.)
www.finanznachrichten.de - April 8 at 5:20 PM
Pacira Pharmaceuticals Inc. (PCRX) Expected to Post Earnings of $0.06 Per SharePacira Pharmaceuticals Inc. (PCRX) Expected to Post Earnings of $0.06 Per Share
www.americanbankingnews.com - April 8 at 7:28 AM
Pacira Announces FDA Approval of Supplemental New Drug Application for EXPAREL® as a Nerve Block to Produce ...Pacira Announces FDA Approval of Supplemental New Drug Application for EXPAREL® as a Nerve Block to Produce ...
globenewswire.com - April 7 at 9:14 AM
Pacira Announces FDA Approval of Supplemental New Drug Application for EXPAREL® as a Nerve Block to Produce Regional AnalgesiaPacira Announces FDA Approval of Supplemental New Drug Application for EXPAREL® as a Nerve Block to Produce Regional Analgesia
finance.yahoo.com - April 7 at 9:14 AM
Pacira Pharmaceuticals (PCRX) Receives Outperform Rating from WedbushPacira Pharmaceuticals (PCRX) Receives Outperform Rating from Wedbush
www.americanbankingnews.com - April 5 at 12:39 PM
Pacira Pharmaceuticals Inc. (PCRX) Given Average Rating of "Hold" by BrokeragesPacira Pharmaceuticals Inc. (PCRX) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 4 at 1:39 AM
Pacira Pharmaceuticals (PCRX) Down 4.7% Since Earnings Report: Can It Rebound?Pacira Pharmaceuticals (PCRX) Down 4.7% Since Earnings Report: Can It Rebound?
finance.yahoo.com - April 2 at 9:19 AM
Pacira Pharmaceuticals (PCRX) PT Lowered to $52.00 at Jefferies GroupPacira Pharmaceuticals (PCRX) PT Lowered to $52.00 at Jefferies Group
www.americanbankingnews.com - March 31 at 8:16 PM
Pacira Pharmaceuticals (PCRX) Rating Reiterated by HC WainwrightPacira Pharmaceuticals (PCRX) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - March 31 at 8:16 PM
Pacira Pharmaceuticals (PCRX) Downgraded to Sell at Zacks Investment ResearchPacira Pharmaceuticals (PCRX) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - March 29 at 10:49 PM
Pacira operating chief bids adieuPacira operating chief bids adieu
seekingalpha.com - March 29 at 4:58 PM
Pacira Pharmaceuticals (PCRX) Cut to "Sell" at BidaskClubPacira Pharmaceuticals (PCRX) Cut to "Sell" at BidaskClub
www.americanbankingnews.com - March 27 at 3:28 PM
Pacira Pharmaceuticals (PCRX) Receives Hold Rating from OppenheimerPacira Pharmaceuticals (PCRX) Receives Hold Rating from Oppenheimer
www.americanbankingnews.com - March 24 at 2:45 PM
$74.39 Million in Sales Expected for Pacira Pharmaceuticals Inc (PCRX) This Quarter$74.39 Million in Sales Expected for Pacira Pharmaceuticals Inc (PCRX) This Quarter
www.americanbankingnews.com - March 24 at 8:10 AM
FY2018 EPS Estimates for Pacira Pharmaceuticals Inc Boosted by Seaport Global Securities (PCRX)FY2018 EPS Estimates for Pacira Pharmaceuticals Inc Boosted by Seaport Global Securities (PCRX)
www.americanbankingnews.com - March 22 at 10:44 AM
Pacira Pharmaceuticals Inc (PCRX) Expected to Post Earnings of $0.06 Per SharePacira Pharmaceuticals Inc (PCRX) Expected to Post Earnings of $0.06 Per Share
www.americanbankingnews.com - March 22 at 8:00 AM
Pacira Pharmaceuticals Sees Unusually High Options Volume (PCRX)Pacira Pharmaceuticals Sees Unusually High Options Volume (PCRX)
www.americanbankingnews.com - March 22 at 7:26 AM
Pacira Pharmaceuticals (PCRX) PT Lowered to $31.00Pacira Pharmaceuticals (PCRX) PT Lowered to $31.00
www.americanbankingnews.com - March 21 at 3:56 PM
Seaport Global Securities Reiterates Buy Rating for Pacira Pharmaceuticals (PCRX)Seaport Global Securities Reiterates Buy Rating for Pacira Pharmaceuticals (PCRX)
www.americanbankingnews.com - March 20 at 11:30 AM

SEC Filings

Pacira Pharmaceuticals (NASDAQ:PCRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Pacira Pharmaceuticals (NASDAQ:PCRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Pacira Pharmaceuticals (NASDAQ PCRX) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.